Abstract: Biofilm formation by pathogenic bacteria is ah allmark of chronic infections.Inmany cases,lectins play key roles in establishing biofilms.T he pathogen Pseudomonas aeruginosa often exhibiting various drug resistances employs its lectins LecA and LecB as virulence factors and biofilm building blocks.T herefore,i nhibition of the function of these proteins is thought to have potential in developing "pathoblockers" preventing biofilm formation and virulence.A covalent lectin inhibitor specific to ac arbohydrate binding site is described for the first time.I ts application in the LecAspecific in vitro imaging of biofilms formed by P. aeruginosa is also reported.
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Lectins are carbohydrate-binding proteins with very diverse functions that are found in all domains of life.
[1] These proteins play crucial roles in numerous processes such as cellcell recognition, infection processes,a nd immune defense. They are generally characterized by an intermediate to low affinity towards their carbohydrate ligands that is often overcome by Nature through multivalencyo fb oth the lectin receptors and their carbohydrate ligands resulting in avidity with an increase in apparent affinity.
Because these carbohydrate-binding proteins play essential roles in an umber of pathological processes,t hey have become attractive targets for therapy.However,the fact that lectins display moderate affinities to their ligands renders this class of proteins as difficult targets for drugs. [2] Despite this drawback, an umber of recent success stories impressively demonstrated their potential for therapy:t he selectin antagonist GMI-1070 is currently in phase III clinical trials,a nd various FimH inhibitors are in the late preclinical stage. [2, 3] Lectins are involved in infections with the Gram-negative bacterium P. aeruginosa, one important member of the often highly drug-resistant ESKAPE pathogens,w hich are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, P. aeruginosa,and Enterobacter species,a nd currently cause most of the severe hospital infections in western countries. [4] Thet wo bacterial lectins, [5] LecA and LecB,a re virulence factors and important for bacterial adhesion and biofilm formation.
[6] Thel atter is especially problematic as resistance against antibiotics inside ab iofilm is increased by af actor of 10-1000. [7] Thus,t he inhibition of these lectins provides ap romising way to dismantle the bacterium from the protective biofilm environment and restore immune defense and activity of antibiotics. [8] Current approaches to inhibit both lectins range from small molecules to multivalent structures and are summarized in recent reviews.
[9] We focus on the development of small molecules and recently published various potent glycomimetic inhibitors for the high affinity lectin LecB as inhibitors of P. aeruginosa adhesion. [10] In contrast, LecA only has an intermediate affinity for its monovalent d-galactose-derived ligands in the 50-100 mm range. [5, 11] Phenyl b-d-galactosides and derivatives showed an increased affinity of approximately 10 mm,for example compound 1 (Figure 1 ), but despite ahigh number of derivatives analyzed, no further significant increase in potencyc ould be achieved. [12] Covalent inhibition is one strategy to avoid dissociation of the inhibitor from the target and thus to persistently inactivate proteins.T od ate,aspecific covalent inhibition of the carbohydrate binding site in alectin has not been achieved despite attempts using squaric acid to target FimH [13] or photoactivatable substituents for the targeting of galectins. [14] Thelatter probes covalently bind to unspecific residues of the protein in proximity (3 )t ot he photoactivated center. The crystal structure of LecA [11a, 15] reveals the presence of one cysteine residue (Cys62) in the carbohydrate binding domain (Figure 1 ). Thes pecific targeting of cysteine residues with electrophilic warheads is ag eneral strategy in the search for cysteine protease inhibitors, [16] but has never been addressed in carbohydrate recognition domains.T ot arget Cys62, we designed the two diastereoisomeric galactose-derived epoxides 2 and 3 (Figure 1 ) as potential covalent active site inhibitors of LecA.
The8 -step synthesis of epoxides 2 and 3 started from dgalactose (4), with epoxidation as the last step (Scheme 1). Galactose 4 was protected as diacetonide (5)a nd the free primary hydroxy group was oxidized under Swern conditions (6)ingood yields.Then, heptose 7 was established in aWittig reaction followed by ac hange in protecting groups from acetonides to acetates (8) . Lewis acid catalyzed glycosylation of phenol with 8 gave phenyl b-glycoside 9 in good yield. Glycoside 9 was deprotected in aZemplØntransesterification reaction to give olefin 10 in 97 %y ield. Late-stage oxidation with mCPBAyielded the two diasteroisomeric epoxides 2 and 3 in 9% and 19 %, respectively.The stereochemistry of 3 was established by X-ray crystallography in complex with LecA (see Figure 3 ).
Both epoxides 2 and 3 and olefin 10 were then tested in ar ecently developed competitive binding assay [12d] for inhibition of LecA. No inhibition was observed for olefin 10 up to 3mm.I nc ontrast, the epoxides showed as trong diastereoselectivity for inhibition of LecA: 3 was ag ood inhibitor with an IC 50 = 64 mm,whereas its diastereomer 2 was not recognized (IC 50 > 3mm), indicating aspecific binding of epoxide 3 to LecA. Covalent inhibitors usually show at ime dependent reduction of IC 50 sd ue to the accumulation at the protein. We have therefore studied the time dependencyo f the binding of 2, 3,a nd phenyl b-d-galactoside to LecA (Supporting Information, Figure S21 ). TheI C 50 of the latter non-covalent inhibitor stayed constant over time,i nactive diastereomer 2 remained inactive,w hereas the binding epoxide diastereomer 3 showed at ime dependent decrease of the IC 50 values,indicative for covalent binding.
To assess the binding mode of 3 with LecA, we analyzed LecA in presence and absence of 3 by mass spectrometry (Figure 2 ). LC-MS measurements on intact protein level showed am ass shift of 268.1 Da when incubated with 3 and thus prove ac ovalent binding of the epoxide to LecA (Figure 2A,B) . Attempts to enzymatically or chemically digest the LecA complex failed due to the extraordinary stability of LecA. To localize the binding site of the epoxide, an MS-based sequencing using MALDI in source decay (ISD) was therefore performed for both samples ( Figure 2C ). MALDI-ISD experiments with c-ion series annotated in ar ange from 5000 to 8000 m/z were instrumental to identify the peptide sequence ranging from Arg 48 to Thr74a nd Asn 71, respectively.F or the LecA sample co-incubated with 3,amass increase of 268 Da to the c62 ion indicated the binding of compound 3 to Cys62 of LecA, with some unspecific binding to Cys57 also detected. Based on the mass increase of 268 Da to the c62 ion, 3 showed covalent binding to LecA and the nucleophile for the epoxide ringopening was the sulfhydryl group of Cys62 in the carbohydrate recognition domain.
We then crystallized LecA in complex with epoxide 3 and solved the structure by X-ray crystallography (Figure 3) . In this complex, 3 adopts ac oordination to the calcium ion bound to LecA as it had been reported for other galactosides before.
[11a, 15] Surprisingly,d espite its orientation towards Cys62, the epoxide moiety in 3 is still intact and the covalent adduct could not be observed in this structure.T hese differences to the covalent adduct detected by mass spectrometry are likely ar esult of the different pH values of the buffers employed:lectin binding assays and mass spectrometry were performed at ap hysiologically buffered pH (7.4), whereas LecA was crystallized at pH 4.6. Numerous attempts to obtain LecA crystals with 3 as acovalent adduct by cocrystallization or soaking at neutral pH have been unsuccessful to date.All data collection of protein crystals incubated with diastereomeric epoxide 2 led to empty binding sites confirming the low affinity of 2 for LecA.
To exploit this unique covalent lectin ligand for biological applications such as lectin specific staining, we synthesized alkyne-bearing derivatives that were then coupled to af luorescent azide in aH uisgen dipolar cycloaddition (Scheme 2). Glycosyl donor 8 was reacted under Lewis acid catalysis with the acceptor monopropargyl hydroquinone to give the glycoside 11.H ere,w ef irst oxidized the peracetylated olefin 11 using mCPBAand the two diasteromeric epoxides 12 and 13 were obtained after chromatographic separation in 21 %and 46 %y ield, respectively.S ubsequently,t he acetates were removed in aZemplØntype reaction to individually give 14 or 
15
.B oth were then tested for inhibition of LecA showing ac omparable diastereoselectivity as observed for the unsubstituted phenyl derivatives 2 and 3 before:6 d epoxide 15 inhibited LecA with an IC 50 of 109 mm,w hereas the diastereomeric 6l epoxide 14 was inactive (IC 50 > 3mm). The stereochemistry of 14 and 15 was unambiguously assigned by combining the activity data and NMR chemical shift and coupling constant analysis and comparison with analogues 2 and 3.T he active diasteromer 15 was then coupled in ac opper(II)-catalyzed click reaction to the azide 16 [17] to give fluorescent probe 17 in good yields.
Thec ovalent nature of the binding of fluoresceinederivative 17 was then further studied by incubation with LecA. Complexes of LecA with 17 or with an on-covalent analogue 18 were performed as observed by high fluorescence polarization. In contrast to the covalent complex of 17 with LecA, 18 could be completely displaced from LecA with the competitive inhibitor methyl galactoside (Supporting Information, Figure S22) . Furthermore,the complex of LecA with 17 was analyzed by polyacrylamide gel electrophoresis under denaturing conditions (Figure 4 ). LecA incubated with 17 gave as ingle fluorescent band that was also stained by Coomassie corresponding to the molecular weight of the denatured monomer of LecA and thus yields further evidence for covalent binding.
Tools to visualize the presence of carbapenem-resistant bacterial pathogens in at est tube by specific activity-based probes have recently been reported. [18] Thev isualization of bacterial biofilm structures is of outstanding current interest, both, in vitro and in vivo. [19] LecA is involved in the biofilm formation of P. aeruginosa and LecA-deficient strains were shown to have thinner biofilms with ar educed biomass. [6b, 20] Because the expression of LecA is upregulated in biofilms and it is located extracellularly, [6b, 21] this protein is apromising target for the imaging of biofilms.W et herefore explored whether the LecA-directed epoxides reported here can specifically stain biofilms of P. aeruginosa. Bacterial biofilms were grown using mCherry-expressing PAO1 wildtype bacteria and the corresponding LecA-deficient strain PAO1 DlecA and then analyzed by confocal fluorescence microscopy ( Figures 5, 6 ). Under shaking growth conditions,bacterial aggregates [22] of the biofilm were observed in the PAO1 wildtype strain, whereas the DlecA strain generally showed aheavily reduced number of aggregates with smaller sizes and therefore also ah igher number of planktonic bacteria since bacterial growth is comparable (Figures 5, 6 ; Supporting Information, Figure S23 ). After addition of the LecAdirected dye 17 to the bacterial cultures,aspecific staining of the wildtype biofilm aggregates was detected and no staining was visible in case of the aggregates formed by the DlecA strain. Thegreen fluorescence originating from 17 was observed on the entire structure of the wildtype bacterial aggregates,w hereas no or only av ery faint color on the surface of the DlecA strain aggregates was observed without any detectable fluorophore inside these aggregates.T he largest aggregate found for the DlecA strain was also analyzed (Supporting Information, Figures S24-S26 ) and staining was LecA-specific and independent of aggregate size.T hus,t he bacterial lectin LecA can be exploited as atarget to visualize biofilms of P. aeruginosa using conjugates of LecA-ligands, such as the galactose-derived epoxide 17.
In summary,w eh ave developed the first covalent inhibitor of carbohydrate binding sites by rational structurebased design. Both diastereomers of the epoxygalactohepto- side 2 and 3 were synthesized and biologically evaluated. LecA displayed as trong diastereoselectivity for the 6d epimer 3 over its 6l isomer 2.T he binding site and its covalent nature at physiological pH was established using mass spectrometry-based sequencing and the non-covalent crystal structure of 3 in complex with LecA was solved at pH 4.6. Finally,weused the fluoresceine-derivative 17 for the LecA-specific staining of P. aeruginosa biofilms.S uch conjugates may lead to the development of pathogen-specific imaging agents to localize bacterial biofilm-associated infections inside an infected host enabling pathogen-and tissuedirected therapy. [23] Acknowledgements 
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